Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal
Ailing Li(Shanghai Medical College of Fudan University), Andrea G. Hohmann(Indiana University Bloomington)
Cited by 68
Related Papers
Slowly Signaling G Protein–Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence
|Molecular Pharmacology|2017|87
Catecholic Isoquinolines from<i>Portulaca oleracea</i>and Their Anti-inflammatory and β<sub>2</sub>-Adrenergic Receptor Agonist Activity
|Journal of Natural Products|2018|37
Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception
|Neuropharmacology|2024|8
Negative allosteric modulation of cannabinoid CB <sub>1</sub> receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception
|bioRxiv (Cold Spring Harbor Laboratory)|2024|2
Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural reward
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0